{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:40:07Z","timestamp":1793716807908,"version":"4.6.1"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,8,4]],"date-time":"2007-08-04T00:00:00Z","timestamp":1186185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Fluticasone furoate is a novel\u2010enhanced affinity glucocorticoid and its long\u2010term safety must be assessed. This study was designed to assess the safety and tolerability of 12\u2010month intranasal administration of fluticasone furoate in adult and adolescent patients with perennial allergic rhinitis (PAR).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> In this randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study, 806 patients with PAR were randomized to once daily (od) fluticasone furoate nasal spray 110\u2003\u03bcg (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>605) or vehicle placebo nasal spray (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>201) for 12\u2003months, following a 7\u2010 to 14\u2010day screening period. Safety was assessed by monitoring adverse events (AEs), 24\u2010h urinary cortisol excretion, nasal and ophthalmic examinations, electrocardiograms and clinical laboratory tests. Plasma concentrations of fluticasone furoate were determined from blood samples.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Fluticasone furoate was well tolerated. The incidence of most AEs was similar to that observed with placebo, with the exception of epistaxis, which was more frequently reported on active treatment. There were no clinically meaningful differences between fluticasone furoate and placebo in terms of safety assessments, including mean changes in ophthalmic parameters and 24\u2010h urine cortisol excretion. Plasma concentrations of fluticasone furoate were not quantifiable in the majority of patients following intranasal administration.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Long\u2010term (12\u2010month) administration of fluticasone furoate 110\u2003\u03bcg od revealed an AE profile typical of the intranasal corticosteroid class in both adult and adolescent patients with PAR, with no evidence of clinically relevant systemic corticosteroid exposure.<\/jats:p>","DOI":"10.1111\/j.1398-9995.2007.01521.x","type":"journal-article","created":{"date-parts":[[2007,8,7]],"date-time":"2007-08-07T03:05:52Z","timestamp":1186455952000},"page":"1071-1077","source":"Crossref","is-referenced-by-count":69,"title":["Long\u2010term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis"],"prefix":"10.1111","volume":"62","author":[{"given":"A.","family":"Rosenblut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. G.","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Faris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. J.","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63155-9"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01054.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01144.x"},{"key":"e_1_2_6_5_2","first-page":"163","article-title":"Inflammatory issues in allergic rhinitis and asthma","volume":"26","author":"Frieri M","year":"2005","journal-title":"Allergy Asthma Proc"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00526.x"},{"key":"e_1_2_6_8_2","volume-title":"The Allergy Report","author":"Task Force on Allergic Disorders","year":"2000"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.110038"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00370.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2003.10.001"},{"key":"e_1_2_6_12_2","article-title":"Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects","volume":"98","author":"Allen A","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2007.28.2983"},{"key":"e_1_2_6_14_2","volume-title":"Expert Panel Report: Guidelines for the diagnosis and management of asthma: update on selected topics","author":"National Asthma Education and Prevention Program","year":"2002"},{"key":"e_1_2_6_15_2","volume-title":"Global strategy for asthma management and prevention","author":"Global Initiative for Asthma","year":"2004"},{"key":"e_1_2_6_16_2","volume-title":"The extent of population exposure to assess clinical safety for drugs intended for long\u2010term treatment of non\u2010life\u2010threatening conditions","author":"European Medicines Agency","year":"1995"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326120-00003"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1258\/002221503322542818"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2003.10.007"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(93)90317-9"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63502-8"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63030-X"},{"key":"e_1_2_6_23_2","volume-title":"Efficacy and safety of mometasone furoate nasal spray vs fluticasone propionate nasal spray and vs placebo in the treatment of perennial allergic rhinitis (PAR). From summary basis of approval (SBA) for Nasonex","author":"Schering Data on File: Trial C94\u2010052","year":"2007"},{"key":"e_1_2_6_24_2","volume-title":"Long\u2010term safety of mometasone furoate nasal spray in the treatment of perennial allergic rhinitis (PAR). From summary basis of approval (SBA) for Nasonex","author":"Schering Data on File: Trial C93\u2010014","year":"2007"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.01843.x"},{"key":"e_1_2_6_26_2","first-page":"332","article-title":"Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis","volume":"67","author":"Nathan RA","year":"1991","journal-title":"Ann Allergy"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70085-5"},{"key":"e_1_2_6_28_2","first-page":"115","article-title":"Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic\u2010pituitary\u2010adrenal\u2010axis function","volume":"25","author":"Sheth KK","year":"2004","journal-title":"Allergy Asthma Proc"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286437"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2007.01521.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2007.01521.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:50:12Z","timestamp":1697417412000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2007.01521.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,4]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1398-9995.2007.01521.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2007.01521.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,4]]}}}